This study is looking at two oral medications, orforglipron and phentermine, to see if they can help people maintain weight loss after stopping injectable GLP-1 (glucagon-like peptide-1) medications like semaglutide or tirzepatide. You might be able to join if you are between 18 and 80 years old, have a history of obesity (BMI ≥30 kg/m²), and have lost at least 10% of your body weight using a GLP-1 medication within the last 8 weeks. The main goal is to see how much your body weight changes after 6 months on one of these new medications. The study is currently unclear on its recruitment status and plans to enroll 60 participants.

Study design

This interventional study plans to enroll 60 participants to compare the effects of orforglipron and phentermine.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 6 months, indicating follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.